Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Trevi Therapeutics 14.25M share Spot Secondary priced at $1.93 » 07:07
09/23/22
09/23
07:07
09/23/22
07:07
TRVI

Trevi Therapeutics

$1.94 /

-0.265 (-12.02%)

SVB Securities, Stifel…

SVB Securities, Stifel and Oppenheimer acted as joint book running managers for the offering.

ShowHide Related Items >><<
TRVI Trevi Therapeutics
$1.94 /

-0.265 (-12.02%)

TRVI Trevi Therapeutics
$1.94 /

-0.265 (-12.02%)

06/29/22 Needham
Trevi Therapeutics price target raised to $10 from $8 at Needham
05/24/22 Oppenheimer
Trevi Therapeutics initiated with an Outperform at Oppenheimer
03/29/22 Aegis
Trevi Therapeutics initiated with a Buy at Aegis
TRVI Trevi Therapeutics
$1.94 /

-0.265 (-12.02%)

  • 23
    Sep
TRVI Trevi Therapeutics
$1.94 /

-0.265 (-12.02%)

TRVI Trevi Therapeutics
$1.94 /

-0.265 (-12.02%)

Over a week ago
On The Fly
Fly Intel: After-Hours Movers » 17:54
09/22/22
09/22
17:54
09/22/22
17:54
FLUX

Flux Power

$2.53 /

-0.34 (-11.85%)

, CAMP

CalAmp

$4.89 /

-0.065 (-1.31%)

, DLNG

Dynagas LNG

$3.33 /

-0.04 (-1.19%)

, GWRE

Guidewire

$59.46 /

-1.46 (-2.40%)

, RSSS

Research Solutions

$1.85 /

-0.01 (-0.54%)

, COST

Costco

$487.20 /

-6.64 (-1.34%)

, EDAP

EDAP TMS

$8.58 /

-0.325 (-3.65%)

, TRVI

Trevi Therapeutics

$1.94 /

-0.265 (-12.02%)

, APEI

American Public Education

$8.30 /

-0.06 (-0.72%)

Check out this evening's…

ShowHide Related Items >><<
TRVI Trevi Therapeutics
$1.94 /

-0.265 (-12.02%)

GWRE Guidewire
$59.46 /

-1.46 (-2.40%)

FLUX Flux Power
$2.53 /

-0.34 (-11.85%)

EDAP EDAP TMS
$8.58 /

-0.325 (-3.65%)

DLNG Dynagas LNG
$3.33 /

-0.04 (-1.19%)

COST Costco
$487.20 /

-6.64 (-1.34%)

CAMP CalAmp
$4.89 /

-0.065 (-1.31%)

APEI American Public Education
$8.30 /

-0.06 (-0.72%)

FLUX Flux Power
$2.53 /

-0.34 (-11.85%)

02/11/22 Maxim
Flux Power price target lowered to $8 from $13 at Maxim
10/05/21 H.C. Wainwright
Flux Power initiated with a Buy at H.C. Wainwright
09/28/21 Maxim
Flux Power price target lowered to $13 from $15 at Maxim
CAMP CalAmp
$4.89 /

-0.065 (-1.31%)

08/16/22 Craig-Hallum
Craig-Hallum upgrades CalAmp to Buy, raises price target to $10
08/16/22 Craig-Hallum
CalAmp upgraded to Buy from Hold at Craig-Hallum
06/24/22 Goldman Sachs
Goldman Sachs cuts CalAmp EBITDA estimates on lower margin forecasts
03/25/22 Jefferies
CalAmp price target lowered to $13 from $16 at Jefferies
DLNG Dynagas LNG
$3.33 /

-0.04 (-1.19%)

04/27/22 Jefferies
Dynagas LNG reinstated with a Hold at Jefferies
GWRE Guidewire
$59.46 /

-1.46 (-2.40%)

09/12/22 Citi
Guidewire price target lowered to $79 from $88 at Citi
09/08/22 Baird
Guidewire price target lowered to $81 from $99 at Baird
09/07/22 JMP Securities
Guidewire price target lowered to $95 from $110 at JMP Securities
09/07/22 RBC Capital
Guidewire price target lowered to $100 from $125 at RBC Capital
RSSS Research Solutions
$1.85 /

-0.01 (-0.54%)

COST Costco
$487.20 /

-6.64 (-1.34%)

09/21/22 Deutsche Bank
Costco price target raised to $581 from $579 at Deutsche Bank
09/12/22 UBS
Costco likely to post 'healthy upside' in Q4, says UBS
09/01/22 Loop Capital
Costco price target lowered to $585 from $610 at Loop Capital
08/31/22 Baird
Costco sales remain resilient, says Baird
EDAP EDAP TMS
$8.58 /

-0.325 (-3.65%)

05/18/22 Piper Sandler
EDAP TMS price target lowered to $11 from $13 at Piper Sandler
11/19/21 B. Riley
EDAP TMS price target lowered to $10 from $13 at B. Riley
TRVI Trevi Therapeutics
$1.94 /

-0.265 (-12.02%)

06/29/22 Needham
Trevi Therapeutics price target raised to $10 from $8 at Needham
05/24/22 Oppenheimer
Trevi Therapeutics initiated with an Outperform at Oppenheimer
03/29/22 Aegis
Trevi Therapeutics initiated with a Buy at Aegis
APEI American Public Education
$8.30 /

-0.06 (-0.72%)

08/11/22 Truist
American Public Education price target lowered to $16 from $21 at Truist
08/10/22 Barrington
American Public Education price target lowered to $15 from $20 at Barrington
05/12/22 Truist
American Public Education price target lowered to $21 from $26 at Truist
05/11/22 Barrington
American Public Education price target lowered to $20 from $25 at Barrington
TRVI Trevi Therapeutics
$1.94 /

-0.265 (-12.02%)

RSSS Research Solutions
$1.85 /

-0.01 (-0.54%)

GWRE Guidewire
$59.46 /

-1.46 (-2.40%)

FLUX Flux Power
$2.53 /

-0.34 (-11.85%)

EDAP EDAP TMS
$8.58 /

-0.325 (-3.65%)

DLNG Dynagas LNG
$3.33 /

-0.04 (-1.19%)

COST Costco
$487.20 /

-6.64 (-1.34%)

CAMP CalAmp
$4.89 /

-0.065 (-1.31%)

APEI American Public Education
$8.30 /

-0.06 (-0.72%)

  • 23
    Sep
  • 23
    Sep
COST Costco
$487.20 /

-6.64 (-1.34%)

GWRE Guidewire
$59.46 /

-1.46 (-2.40%)

FLUX Flux Power
$2.53 /

-0.34 (-11.85%)

COST Costco
$487.20 /

-6.64 (-1.34%)

CAMP CalAmp
$4.89 /

-0.065 (-1.31%)

TRVI Trevi Therapeutics
$1.94 /

-0.265 (-12.02%)

COST Costco
$487.20 /

-6.64 (-1.34%)

Syndicate
Trevi Therapeutics files to sell common stock, no amount given » 16:02
09/22/22
09/22
16:02
09/22/22
16:02
TRVI

Trevi Therapeutics

$1.97 /

-0.235 (-10.66%)

SVB Securities, Stifel…

SVB Securities, Stifel and Oppenheimer & Co. are acting as joint bookrunning managers for the offering. Needham & Company is acting as lead manager for the offering.

ShowHide Related Items >><<
TRVI Trevi Therapeutics
$1.97 /

-0.235 (-10.66%)

TRVI Trevi Therapeutics
$1.97 /

-0.235 (-10.66%)

06/29/22 Needham
Trevi Therapeutics price target raised to $10 from $8 at Needham
05/24/22 Oppenheimer
Trevi Therapeutics initiated with an Outperform at Oppenheimer
03/29/22 Aegis
Trevi Therapeutics initiated with a Buy at Aegis
TRVI Trevi Therapeutics
$1.97 /

-0.235 (-10.66%)

TRVI Trevi Therapeutics
$1.97 /

-0.235 (-10.66%)

Options
Three new option listings and one option delisting on September 19th » 08:30
09/19/22
09/19
08:30
09/19/22
08:30
RUM

Rumble

$12.04 /

+0.405 (+3.48%)

, TRVI

Trevi Therapeutics

$3.21 /

+0.14 (+4.56%)

, CTT

CatchMark Timber

$10.35 /

+ (+0.00%)

New option listings for…

New option listings for September 19th include RUM Stock (RUM), SNPTY Stock (SNPTY), and Trevi Therapeutics Inc (TRVI). Option delistings effective September 19th include Catchmark Timber Trust Inc (CTT).

ShowHide Related Items >><<
TRVI Trevi Therapeutics
$3.21 /

+0.14 (+4.56%)

RUM Rumble
$12.04 /

+0.405 (+3.48%)

CTT CatchMark Timber
$10.35 /

+ (+0.00%)

RUM Rumble
$12.04 /

+0.405 (+3.48%)

TRVI Trevi Therapeutics
$3.21 /

+0.14 (+4.56%)

06/29/22 Needham
Trevi Therapeutics price target raised to $10 from $8 at Needham
05/24/22 Oppenheimer
Trevi Therapeutics initiated with an Outperform at Oppenheimer
03/29/22 Aegis
Trevi Therapeutics initiated with a Buy at Aegis
CTT CatchMark Timber
$10.35 /

+ (+0.00%)

06/02/22 Baird
CatchMark Timber downgraded to Neutral from Outperform at Baird
06/01/22 Stifel
CatchMark Timber downgraded to Hold at Stifel after PotlatchDeltic deal
06/01/22 Raymond James
CatchMark upgraded to Market Perform from Underperform at Raymond James
06/01/22 Stifel
CatchMark Timber downgraded to Hold from Buy at Stifel
TRVI Trevi Therapeutics
$3.21 /

+0.14 (+4.56%)

CTT CatchMark Timber
$10.35 /

+ (+0.00%)

CTT CatchMark Timber
$10.35 /

+ (+0.00%)

Hot Stocks
Trevi Therapeutics announces data from its Phase 2 CANAL trial of Haduvio » 07:36
09/19/22
09/19
07:36
09/19/22
07:36
TRVI

Trevi Therapeutics

$3.21 /

+0.14 (+4.56%)

Trevi Therapeutics…

Trevi Therapeutics announced positive results from the full set of subjects in its Phase 2 Cough And NALbuphine, CANAL, trial of Haduvio for the treatment of chronic cough in IPF. Dr. William Forbes will present the data during the Company's Virtual R&D Day today. Following the statistically significant efficacy results from the CANAL trial's interim analysis conducted in February 2022, the Company concluded enrollment early in March 2022 and allowed enrolled subjects to complete the trial. Topline data from the full set of subjects in the Phase 2 CANAL trial was statistically significant for the trial's primary endpoint and showed a 52.5% change compared to placebo, with a 75.1% reduction in the geometric mean percent change in daytime cough frequency for Haduvio. "We are pleased to announce the positive results from the full set of subjects from the CANAL trial, which are consistent with the previously announced interim analysis and further demonstrated that Haduvio has the potential to reduce IPF patients' cough," said Jennifer Good, President and CEO of Trevi Therapeutics. "We analyzed the change of 24hr cough frequency as well as daytime cough frequency and observed consistent reductions for both measurements. There are no approved therapies for chronic cough in these patients, and we are excited to continue our development in this indication and look forward to starting our next clinical trial for these patients in the first half of 2023. We would like to thank the CANAL trial participants and investigators for their contribution to this research as we look to improve IPF patients' quality of life." Additional Efficacy Analyses: Haduvio subjects had a 76.1% reduction in 24hr cough frequency compared to a 25.3% of placebo subjects, a 50.8% placebo-adjusted change. In a post-hoc analysis, 97% of Haduvio subjects had at least a 30% reduction in 24hr cough frequency compared to 35% of placebo subjects, signifying a clinically meaningful reduction in cough. Subjects on Haduvio experienced a statistically significant improvement as measured by their patient reported outcomes compared to placebo over the 3-week treatment period in the EXACT2: Cough Frequency Score and Cough Severity Numerical Rating Scale. Based on the Clinical Global Impression of Change rating measuring clinicians' view of change since the start of the trial, 62% of Haduvio subjects improved vs. baseline compared to 19% of placebo subjects. Safety and Tolerability Results: The safety results of the trial were generally consistent with the known safety profile of Haduvio from previous trials.

ShowHide Related Items >><<
TRVI Trevi Therapeutics
$3.21 /

+0.14 (+4.56%)

TRVI Trevi Therapeutics
$3.21 /

+0.14 (+4.56%)

06/29/22 Needham
Trevi Therapeutics price target raised to $10 from $8 at Needham
05/24/22 Oppenheimer
Trevi Therapeutics initiated with an Outperform at Oppenheimer
03/29/22 Aegis
Trevi Therapeutics initiated with a Buy at Aegis
TRVI Trevi Therapeutics
$3.21 /

+0.14 (+4.56%)

Over a quarter ago
Recommendations
Trevi Therapeutics price target raised to $10 from $8 at Needham » 16:20
06/29/22
06/29
16:20
06/29/22
16:20
TRVI

Trevi Therapeutics

$2.47 /

+0.435 (+21.43%)

Needham analyst Serge…

Needham analyst Serge Belanger raised the firm's price target on Trevi Therapeutics to $10 from $8 and keeps a Buy rating on the shares. The stock closed Wednesday up 21% to $2.45. The Phase 2b/3 trial evaluating Haduvio as a treatment for prurigo nodularis successfully met the key primary and secondary endpoints, Belanger tells investors in a research note. The analyst says Haduvio had a quick onset of action reaching statistical significance at six-weeks with efficacy that had yet to plateau at the week-14 readout. Belanger believes Trevi's valuation discounts Haduvio's potential and upped the price target to reflect "additional de-risking" of the prurigo nodularis program.

ShowHide Related Items >><<
TRVI Trevi Therapeutics
$2.47 /

+0.435 (+21.43%)

TRVI Trevi Therapeutics
$2.47 /

+0.435 (+21.43%)

05/24/22 Oppenheimer
Trevi Therapeutics initiated with an Outperform at Oppenheimer
03/29/22 Aegis
Trevi Therapeutics initiated with a Buy at Aegis
TRVI Trevi Therapeutics
$2.47 /

+0.435 (+21.43%)

Hot Stocks
Trevi Therapeutics' Haduvio meets efficacy endpoint in Phase 2b/3 trial » 07:40
06/29/22
06/29
07:40
06/29/22
07:40
TRVI

Trevi Therapeutics

$2.02 /

+ (+0.00%)

Trevi Therapeutics…

Trevi Therapeutics announced positive results from its Phase 2b/3 PRISM trial of Haduvio in treating prurigo nodularis. Prurigo nodularis is a chronic disease characterized by severe pruritus and the presence of nodules, lesions, and excoriations. Chronic pruritus is a key contributing cause of prurigo nodularis and manifests in an itch-scratch cycle, which is difficult to disrupt. There are no approved therapies for prurigo nodularis. In the Phase 2b/3 trial, results comparing subjects randomized to Haduvio monotherapy or placebo showed: 25% of Haduvio subjects evaluated at week 14 met the primary endpoint of a 4-point reduction in WI-NRS from baseline compared to 14% of placebo subjects; Haduvio subjects experienced significantly greater improvements in ItchyQoL vs. placebo at week 14, which was statistically significant across each of the three domains. ItchyQoL is used to measure how pruritus impacts a subject's quality-of-life. 55% of Haduvio subjects saw at least a 1-category improvement in the 5-point scale in their Prurigo Activity Scale (pruriginous lesions with excoriations), vs. 38% on placebo (p&#61;0.006) as evaluated at week 14. The safety results of the trial were generally consistent with the known safety profile of Haduvio from previous trials. None of the SAEs were considered by the investigator to be treatment-related. Adverse events most commonly observed with Haduvio were nausea, dizziness, headache, and constipation.

ShowHide Related Items >><<
TRVI Trevi Therapeutics
$2.02 /

+ (+0.00%)

TRVI Trevi Therapeutics
$2.02 /

+ (+0.00%)

05/24/22 Oppenheimer
Trevi Therapeutics initiated with an Outperform at Oppenheimer
03/29/22 Aegis
Trevi Therapeutics initiated with a Buy at Aegis
TRVI Trevi Therapeutics
$2.02 /

+ (+0.00%)

Initiation
Trevi Therapeutics initiated with an Outperform at Oppenheimer » 16:04
05/24/22
05/24
16:04
05/24/22
16:04
TRVI

Trevi Therapeutics

$2.16 /

-0.09 (-4.00%)

Oppenheimer analyst…

Oppenheimer analyst Leland Gershell initiated coverage of Trevi Therapeutics with an Outperform rating and $10 price target, citing the prospects of oral candidate Haduvio to address chronic cough associated with idiopathic pulmonary fibrosis. He also expresses "enthusiasm" for its prospects to treat severe chronic itch and forecasts total peak sales of $750M-plus for Haduvio, Gershell tells investors.

ShowHide Related Items >><<
TRVI Trevi Therapeutics
$2.16 /

-0.09 (-4.00%)

TRVI Trevi Therapeutics
$2.16 /

-0.09 (-4.00%)

03/29/22 Aegis
Trevi Therapeutics initiated with a Buy at Aegis
TRVI Trevi Therapeutics
$2.16 /

-0.09 (-4.00%)

Earnings
Trevi Therapeutics reports Q1 EPS (24c), consensus (29c) » 16:12
05/12/22
05/12
16:12
05/12/22
16:12
TRVI

Trevi Therapeutics

$2.06 /

+0.085 (+4.31%)

As of March 31, 2022, the…

As of March 31, 2022, the company had total cash and cash equivalents of $29.1M. "We are delighted with the significant progress made this year in achieving Trevi's clinical development goals and the advancement of Haduvio," said CEO Jennifer Good. "The interim analysis results of the Phase 2 CANAL study allowed us to end enrollment early in the trial and begin preparations to accelerate development for this indication. Additionally, the successful closing of a $55M private placement on April 11, 2022, allows us to fund the next phase of development for Haduvio in chronic cough in IPF. We look forward to our expected data readout for the Phase 2b/3 PRISM study this quarter and the data readout from the full set of subjects for the Phase 2 CANAL study in the third quarter of this year."

ShowHide Related Items >><<
TRVI Trevi Therapeutics
$2.06 /

+0.085 (+4.31%)

TRVI Trevi Therapeutics
$2.06 /

+0.085 (+4.31%)

03/29/22 Aegis
Trevi Therapeutics initiated with a Buy at Aegis
TRVI Trevi Therapeutics
$2.06 /

+0.085 (+4.31%)

Syndicate
Trevi Therapeutics files to sell 28.96M shares of common stock for holders  16:19
05/02/22
05/02
16:19
05/02/22
16:19
TRVI

Trevi Therapeutics

$2.52 /

-0.12 (-4.55%)

 
ShowHide Related Items >><<
TRVI Trevi Therapeutics
$2.52 /

-0.12 (-4.55%)

TRVI Trevi Therapeutics
$2.52 /

-0.12 (-4.55%)

03/29/22 Aegis
Trevi Therapeutics initiated with a Buy at Aegis
TRVI Trevi Therapeutics
$2.52 /

-0.12 (-4.55%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.